Analyst Ratings for AbCellera Biologics (ABCL)
ABCL Rating Summary
ABCL Price Target Summary
- Highest: $30.00 (Truist Securities)
- Lowest: $4.00 (Leerink)
- Average: $14.10
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$14.10 (+19.5%)
* Over Last 12-Mos
Rating Score: 8.7 / 10
Percentile Rank: 87%
Rating Score: 8.7 / 10
Percentile Rank: 87%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | UBS | Alice Nettleton | New Coverage | Buy (N/A) |
18.00 (N/A) |
12.02 (11.80) |
-1.83% | Details |
| 9/29/2026 | JPMorgan | N/A | New Coverage | Overweight (N/A) |
17.00 (N/A) |
13.92 (11.80) |
-15.23% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
